SINTX Technologies Inc

SINTX Technologies Inc(SINT)股票分析

$1.560

-0.058 (-3.70%)收盘时

Loading chart…
最高
1.640
开盘
1.640
成交量加权均价
1.58
成交量
41.03K
市值
3.17M
最低
1.550
成交额
64.96K
企业价值/息税折旧摊销前利润(TTM)
-0.31

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah.

sintx.com

AI 分析 of SINTX Technologies Inc (SINT)

卖出

SINTX Technologies Inc is not a good buy right now due to its very low RSI of 23.718, indicating oversold conditions, and a significant year-to-date decline of 58.73%. The stock is currently trading at $1.56, which is only 5.2% above its 52-week low of $1.40, suggesting limited upside potential. Additionally, the company has reported substantial net losses, with a net income of -$3,632,000 in Q2 2026, raising concerns about its financial stability. The main risk is its high debt-to-equity ratio of 11.73% in Q1 2026, indicating potential liquidity issues.

估值指标

SINTX Technologies Inc(SINT)当前预期市盈率为 0.00,5 年平均预期市盈率为 -19.40。

预期市盈率

合理
5 年均值 P/E
-19.40
当前P/E
0.00
高估
59.35
低估
-98.14

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-0.32
当前EV/EBITDA
-0.31
高估
0.29
低估
-0.94

预期市销率

合理
5 年均值 P/S
4.14
当前P/S
2.03
高估
8.10
低估
0.19

Alphio AI 对 SINT 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%SINT

$2.63

情景价格

基

基准

基准 · 50%SINT

$1.91

情景价格

悲

悲观

悲观 · 25%SINT

$1.46

情景价格

事件时间线

2026-11-05 (ET)

17:30:00

SINTX Technologies Reports Q3 Revenue of $2.19M

2026-10-01 (ET)

09:30:00

Sintx Technologies Reports $2.2M Revenue for Q3

2026-08-13 (ET)

06:30:00

Selling Stockholders Plan to Sell 1.27M Shares of Common Stock

2026-06-25 (ET)

06:30:00

Sintx Technologies Files to Sell 5.82M Shares of Common Stock

2026-06-22 (ET)

10:00:00

Sintx Technologies Secures Over $3.2M in Orders

资讯

SINT 常见问题 —— 由 Alphio AI 解答

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

SINTX Technologies Inc is not a good buy right now due to its very low RSI of 23.718, indicating oversold conditions, and a significant year-to-date decline of 58.73%. The stock is currently trading at $1.56, which is only 5.2% above its 52-week low of $1.40, suggesting limited upside potential. Additionally, the company has reported substantial net losses, with a net income of -$3,632,000 in Q2 2026, raising concerns about its financial stability. The main risk is its high debt-to-equity ratio of 11.73% in Q1 2026, indicating potential liquidity issues.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易